schizandrol b has been researched along with paclitaxel in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bi, H; Hu, J; Huang, M; Huang, Z; Jin, J; Zhao, L; Zhong, G | 1 |
| Chen, J; Chen, M; Huang, X; Liu, J; Shangguan, M; Wang, T; Wu, S; Yang, Z; Zhang, C; Zhao, S | 1 |
2 other study(ies) available for schizandrol b and paclitaxel
| Article | Year |
|---|---|
Enhancement of oral bioavailability of paclitaxel after oral administration of Schisandrol B in rats.
Topics: Administration, Oral; Animals; Antineoplastic Agents, Phytogenic; Area Under Curve; Biological Availability; Cyclooctanes; Dioxoles; Dose-Response Relationship, Drug; Drug Interactions; Injections, Intravenous; Lignans; Male; Paclitaxel; Rats; Rats, Sprague-Dawley; Schisandra | 2010 |
Gomisin A enhances the antitumor effect of paclitaxel by suppressing oxidative stress in ovarian cancer.
Topics: Animals; Carcinoma, Ovarian Epithelial; Cell Line, Tumor; Cell Proliferation; Complex Mixtures; Cyclin B1; Cyclin-Dependent Kinase 4; Cyclooctanes; Cysteine; Dioxoles; Eosine Yellowish-(YS); Female; Humans; Lignans; Mice; Ovarian Neoplasms; Oxidative Stress; Paclitaxel; Reactive Oxygen Species | 2022 |